In today’s session Bristol-Myers Squibb Co (BMY) recorded an unusually high (1,938) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the March, 2017 put, expecting serious BMY decrease. With 1,938 contracts traded and 20674 open interest for the Mar, 17 contract, it seems this is a quite bearish bet. The option with symbol: BMY170317P00050000 closed last at: $3.45 or 1.4% down. About 7.58 million shares traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has declined 22.38% since March 14, 2016 and is downtrending. It has underperformed by 27.99% the S&P500.
Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on October, 25. They expect $0.63 EPS, up 61.54% or $0.24 from last year’s $0.39 per share. BMY’s profit will be $1.04B for 19.59 P/E if the $0.63 EPS becomes a reality. After $0.69 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -8.70% negative EPS growth.
Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage
Out of 15 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 7 “Hold”. This means 33% are positive. Bristol-Myers Squibb Company has been the topic of 33 analyst reports since July 28, 2015 according to StockzIntelligence Inc. As per Friday, January 22, the company rating was upgraded by Berenberg. UBS upgraded the stock to “Buy” rating in Tuesday, September 29 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Equal-Weight” rating by Barclays Capital on Friday, September 9. The rating was maintained by Barclays Capital with “Equal Weight” on Tuesday, December 1. Societe Generale initiated Bristol-Myers Squibb Co (NYSE:BMY) on Wednesday, April 6 with “Sell” rating. The stock has “Outperform” rating given by Credit Suisse on Monday, May 9. As per Friday, December 18, the company rating was initiated by Atlantic Securities. The firm earned “Hold” rating on Thursday, August 11 by Berenberg. On Monday, May 23 the stock rating was initiated by Hilliard Lyons with “Neutral”. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Hold” rating by Jefferies on Thursday, July 14.
According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.”
Insitutional Activity: The institutional sentiment increased to 0.94 in Q2 2016. Its up 0.01, from 0.93 in 2016Q1. The ratio improved, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Sterneck Mngmt Ltd holds 6,422 shares or 0.31% of its portfolio. Nottingham Advsrs reported 4,683 shares or 0.06% of all its holdings. Jgp Glob Gestao De Recursos Ltda, a Brazil-based fund reported 12,497 shares. Concannon Wealth Management Ltd reported 800 shares or 0.06% of all its holdings. Fayerweather Charles holds 3,050 shares or 0.31% of its portfolio. Heritage Wealth Advsr, a Virginia-based fund reported 3,284 shares. Guggenheim Cap Limited holds 0.18% or 799,831 shares in its portfolio. Busey Trust last reported 19,181 shares in the company. Chesley Taft & Associates Ltd Limited Liability Company has 0.14% invested in the company for 17,974 shares. Marquette Asset has invested 0.1% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Murphy Cap Mngmt accumulated 0.42% or 37,214 shares. Tsp Capital Mgmt Group Incorporated Ltd Llc accumulated 64,435 shares or 2.45% of the stock. Ig Mgmt Limited accumulated 0.11% or 377,817 shares. Td Cap Mgmt Ltd accumulated 0.09% or 3,841 shares. Venbio Select Advisor Ltd Co holds 7.28% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 445,339 shares.
Insider Transactions: Since May 3, 2016, the stock had 0 buys, and 9 selling transactions for $16.83 million net activity. 23,200 shares with value of $1.37 million were sold by ANDREOTTI LAMBERTO on Wednesday, August 24. $2.14M worth of Bristol-Myers Squibb Co (NYSE:BMY) was sold by Bancroft Charles A on Friday, May 20. $255,004 worth of Bristol-Myers Squibb Co (NYSE:BMY) was sold by Caldarella Joseph C. Shares for $5.11 million were sold by LEUNG SANDRA. $2.47M worth of Bristol-Myers Squibb Co (NYSE:BMY) shares were sold by Caforio Giovanni. 11,820 shares with value of $859,219 were sold by Elicker John E on Tuesday, June 14.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $81.70 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 28.89 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.
BMY Company Profile
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Fool.com which released: “CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%” on October 10, 2016, also Fool.com with their article: “Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech …” published on October 17, 2016, Businesswire.com published: “Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for …” on October 14, 2016. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Seekingalpha.com and their article: “Bristol-Myers Squibb: The Opdivo Fiasco” published on October 11, 2016 as well as Fool.com‘s news article titled: “Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today” with publication date: October 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.